Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.

Saved in:
Bibliographic Details
Title: Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
Authors: Ley L; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Holze F; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Arikci D; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Becker AM; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Straumann I; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Klaiber A; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Coviello F; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Dierbach S; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Thomann J; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Duthaler U; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Luethi D; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Varghese N; Psychiatric University Hospital, University of Basel, Basel, Switzerland.; Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland., Eckert A; Psychiatric University Hospital, University of Basel, Basel, Switzerland.; Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland., Liechti ME; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland. matthias.liechti@usb.ch.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. matthias.liechti@usb.ch.
Source: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2023 Oct; Vol. 48 (11), pp. 1659-1667. Date of Electronic Publication: 2023 May 25.
Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8904907 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-634X (Electronic) Linking ISSN: 0893133X NLM ISO Abbreviation: Neuropsychopharmacology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1740-634X
DOI:10.1038/s41386-023-01607-2